COVID-19 Surgery Delays May Mean 2,700 More Breast Cancer Deaths Within 10 Years

COVID-19 Surgery Delays May Mean 2,700 More Breast Cancer Deaths Within 10 Years
Delays in breast cancer surgery due to the COVID-19 pandemic could cost 2,797 additional deaths in the U.S. over the next decade, according to a Kantar Health analysis. Such treatment delays also place patients at a higher risk of metastasis, or cancer spread, potentially increasing healthcare costs in the U.S. by an estimated $376 million over the next 10 years, the analysis suggests. “The effects of the pandemic will be felt deeply in many disease areas, but none more so than in oncology,” Jeremy Brody, chief strategy officer of Kantar Health, said in a press release. “It is important that patients continue to maintain their regular appointments and screenings to detect and treat breast cancer. The COVID-19 global pandemic needs to be a catalyst for the healthcare system to seek new ways to reach patients and ensure early detection screenings continue,” Brody said. The analysis was released as part of Breast Cancer Awareness Month, held each year in October, and is based on Kantar Health’s proprietary
Subscribe or to access all post and page content.